Research programme: vascular protectants - AtheroGenics

Drug Profile

Research programme: vascular protectants - AtheroGenics

Alternative Names: AGI-2048; AGI-2636; AGI-series for respiratory diseases; v-protectants

Latest Information Update: 11 May 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AtheroGenics
  • Class Small molecules
  • Mechanism of Action Antioxidants; Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Asthma; Rheumatoid arthritis

Most Recent Events

  • 14 Jun 2005 Data presented at the 101st International Conference of the American Thoracic Society (ATS-2005) have been added to the Obstructive airways disease pharmacodynamics section ,
  • 14 Oct 2004 This programme is still in active development for Rheumatoid arthritis
  • 14 Nov 2003 Preclinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top